advance
associate
associated
base
benefit
capecitabine
cholangiocarcinoma
ci
clinical
develop
disease
disease-free
drugs
effect
existing
factor
female
gefitinib
Gleason
grading
inhibitor
kinase
level
liposarcoma
median
month
oral
OS
outcome
overall
patients
PFS
phase I
phase II
prognosis
prognostic
receive
recurrence
recurrence-free
relapse-free
resistance
response
review
survival
targets
therapeutical
therapy
trastuzumab
treatment
trial
year